On the eve of the first
anniversary of the moratorium on Bt Brinjal in India, the Foundation
for Biotechnology Awareness and Education (FBAE), a non-profit
organization formed to promote public awareness of scientific issues of
biotechnology and to enhance levels of biotechnology education and
training based in Bangalore has called for an immediate lift on the
moratorium on the commercial release of Bt brinjal.
Reiterating the concerns raised by over 40 Indian scientists at a
workshop organized by the FBAE in July 2010 in New Delhi, and the
memorandum submitted to the central government then, the FBAE cited
recent important publications on the socio-economic benefits such as
better living standards, health and education, and reduced tension,
among the farming community and a healthier product to the consumer,
that would accrue from the adoption of Bt brinjal.
Scientists opined that the moratorium on Bt brinjal was strongly
influenced by those opposed to agricultural biotechnology. They also
suggested that like the Philippines, India should also follow the
credible, critical, and balanced scientific judgment of technologists
and biosecurity experts for the approval of genetically modified crops
such as Bt brinjal.
“The government's decision of imposing a moratorium on Bt brinjal
seriously affected research and development activities in the country's
agricultural biotechnology sector. The moratorium has created a
regulatory uncertainty on the development of all genetically engineered
crops in the country. In a year, there has been no palpable, effective
and time bound effort to lift the moratorium or to resolve the
uncertainties caused by the moratorium,� said Prof C Kameswara Rao,
executive secretary, Foundation for Biotechnology Awareness and
Education (FBAE).
Dr TM Majunath, consultant - agricultural biotechnology, said,
“Considering that the product efficacy, biosafety and environmental
safety of Bt brinjal was evaluated for over seven years, as per
international standards, involving over 200 scientists and more than a
dozen public and private sector research institutions, Bt brinjal
should be commercially released without further delay.�
As per a recent publication from the National Center for Agricultural
Economics and Policy Research, an ICAR institute, Bt brinjal adoption
would add between 30,000 to 119,000 tons to the total production of
brinjal, depending upon the extent of cultivation in different areas/
states. The absolute annual gain at the country level from Bt brinjal
cultivation would be about $127.05 million (
577 crore) at an adoption level of 15
percent, about $257 million at 30 percent and $526 million at 60
percent adoption levels.
Natco challenges Gilead's Tamiflu
patent
Gilead Sciences, a biopharmaceutical company headquartered in
California with operations in North America, Europe and Australia, has
announced receipt of a Paragraph IV Certification Notice Letter
advising that Natco Pharma, an Indian enterprise, submitted an
Abbreviated New Drug Application (ANDA) to the US Food and Drug
Administration (FDA) requesting permission to manufacture and market a
generic version of Tamiflu (oseltamivir phosphate) 75 mg capsules.
In the notice letter, Natco alleges that a patent associated with
Tamiflu – US Patent Number 5,763,483 – owned by Gilead Sciences is
invalid, unenforceable and/o
r will not be infringed by
Natco's
manufacture, use or sale of the product described in its ANDA
submission.
Gilead is currently reviewing the Notice Letter and has 45 days from
the date of receipt to commence a patent infringement lawsuit against
Natco. Such a lawsuit would restrict the FDA from approving Tamiflu's
ANDA for up to 30 months or until a district court decision that is
adverse to Gilead, whichever occurs first. Tamiflu is protected by this
patent, which is listed in the FDA's Approved Drug Products List, and
the patent would need to be invalidated or not infringed upon before a
generic version of Tamiflu could be marketed without liability for
patent infringement. Tamiflu was invented by Gilead Sciences and
licensed to F. Hoffmann-La Roche in 1996.
Tamil Nadu to announce new biotech
policy
In a major step to boost the
biotech industry in Tamil Nadu, the state government is revising its
decade-old biotech policy and coming up with new measures, investments
and expansion plans. Mr MK Stalin, deputy chief minister, Government of
Tamil Nadu, announced that the state government is formulating a new
biotech policy with innovative features.
Speaking at the inauguration of a roundtable on biotechnology
development and its enabled services, organized by the industry
association, CII in Chennai, he said that the state has plans to set up
marine and medicinal plant biotech parks soon. Around 300 acres were
identified to set up a marine biotechnology park, plans are also there
to set up a marine biotechnology park and a medicinal plant biotech
park.
With the success of TICEL Biotechnology Park-I, which was established
with the technical collaboration of Cornell University, US at a cost of
$12 million (
54.76 crore) and now fully occupied, the
government is taking initiatives to drive the growth further. TICEL
Biotechnology Park- II is expected to provide employment opportunities
for 1,500 scientists. The park is expected to be completed in 2011 and
will have a 'biotechnology core facility' to provide scientific and
incubation support to the clients and biotech industries at the cost of
$4.3 million (
19.30 crore), and labs of BSL3 at a cost
of $2million (
7.37 crore).
Mr Stalin also stressed on the need to ensure that any development made
in biotechnology does not erode the genetic pool and the rich diversity
in flora and fauna. According to Mr PM Murali, convenor, Confederation
of Indian Industry (CII) Tamil Nadu Biotechnology Panel; Tamil Nadu has
fallen behind other states such as Maharashtra, Karnataka, Andhra
Pradesh, National Capital Region (NCR) and Gujarat, in spite of having
several advantages in biotechnology. He proposed the need to form a
separate department of biotechnology to enable 'single window
clearance', which may attract a lot of MNCs in this field.
Mr Murali also added that the Indian biotech industry was worth $3
billion (
14,000 crore) last year according to the
BioSpectrum ABLE Survey, and it will expand five-fold by 2015.
Biogenerics worth $70 billion will come off-patent soon and it presents
a great opportunity for Indian companies. It will also generate a lot
of employment.
The conference discussed about the need for a new policy which is
expected to address the needs of the industry like creating
infrastructure, bio-incubator facilities, regulations, human resources
and a common platform for the industry, academia and the government to
communicate, according to a senior official from the government. It
would also elaborate on the funding options and policies to support
biotech research and manufacturing.
DHR frames health research policy
The Department of Health Research (DHR), Ministry of Health &
Family Welfare, Government of India, has sought the public opinion on
its National Health Research Policy survey report. One of the mandates
of the DHR is to improve governance of health research. DHR has asked
for feedbacks to improve the quality and contents of this draft policy.
As a first step, a National Health Research Policy was formulated with
active participation and contributions made by several experts. The
division of non-communicable diseases (NCDs) at Indian Council of
Medical Research (ICMR) was identified as the nodal point for
surveillance of NCDs and their risk factors by the WHO, and multi-site
studies helped in developing a sound strategy for NCD risk factor
surveys at the national level under Integrated Disease Surveillance
Project (IDSP).The ICMR signed a memorandum of understanding with IDSP
for the standardization and quality assurance of the NCD risk factor
surveys under the World Bank-funded IDSP on behalf of Ministry of
Health.
As per IDSP plan, these surveys were to be carried out in three phases
so as to cover all states and union territories in India. In phase I,
the state-based estimates of the risk factors in seven states were
arrived at through the IDSP-identified seven State Survey Agencies,
five Regional Research Centers and a National Nodal Agency under the
overall guidance and supervision of ICMR headquarters through the
National Technical Advisory Committee.